Citations

Mayo Clinic

Clear

2205 citation(s) found for "Young, L".

Hsp70–Bag3 Interactions Regulate Cancer-Related Signaling Networks
Colvin, Teresa A., Gabai, Vladimir L. , Calderwood, Stuart K. , Gummuluru, Suryaram , Matchuk, Olga N. , Smirnova, Svetlana G. , Orlova, Nina V. , Замулаева, И. А. , Li, Xiaokai, Young, Zapporah T. , Rauch, Jennifer N. , Gestwicki, Jason E. , Takayama, Shinichi , Sherman, Michael Y. , Gong, Jianlin , Li, Hu , Garcia‐Marcos, Mikel , Sherman, Michael Y.

Cancer Research | July 4, 2014 | Volume: 74 | Issue: 17 | Pages: 4731-4740

10.1158/0008-5472.can-14-0747 | PMID 24994713 Get It

Abstract Bag3, a nucleotide exchange factor of the heat shock protein Hsp70, has been implicated in cell signaling. Here, we report that Bag3 interacts with the SH3 domain of Src, thereby mediating the effects of Hsp70 on Src signaling. Using several complementary approaches, we established that the Hsp70–Bag3 module is a broad-acting regulator of cancer cell signaling by modulating the activity of the transcription factors NF-κB, FoxM1, Hif1α, the translation regulator HuR, and the cell-cycle regulators p21 and survivin. We also identified a small-molecule inhibitor, YM-1, that disrupts the Hsp70–Bag3 interaction. YM-1 mirrored the effects of Hsp70 depletion on these signaling pathways, and in vivo administration of this drug was sufficient to suppress tumor growth in mice. Overall, our results defined Bag3 as a critical factor in Hsp70-modulated signaling and offered a preclinical proof-of-concept that the Hsp70–Bag3 complex may offer an appealing anticancer target. Cancer Res; 74(17); 4731–40. ©2014 AACR.
External Validation of a Multiplex Urinary Protein Panel for the Detection of Bladder Cancer in a Multicenter Cohort
Chen, Li-Mei, Chang, Myron, Dai, Yunfeng , Chai, Karl X., Dyrskjøt, Lars , Sänchez‐Carbayo, Marta, Szarvas, Tibor , Zwarthoff, Ellen C. , Lokeshwar, Vinata B. , Jerónimo, Cármen , Parker, Alexander S. , Ross, Shanti, Borre, Michael , Ørntoft, Torben F., Jaeger, T., Beukers, Willemien, López, Luis E., Henrique, Rui , Urquidi, Virginia, Goodison, Steve , Rosser, Charles J. , Chen, Li‐Mei , Young, Paul R.

Cancer Epidemiology, Biomarkers & Prevention | June 12, 2014 | Volume: 23 | Issue: 9 | Pages: 1804-1812

10.1158/1055-9965.epi-14-0029 | PMID 24920641 Get It

Abstract Background: Because of the faltering sensitivity and/or specificity, urine-based assays currently have a limited role in the management of patients with bladder cancer. The aim of this study was to externally validate our previously reported protein biomarker panel from multiple sites in the United States and Europe. Methods: This multicenter external validation study included a total of 320 subjects (bladder cancer = 183). The 10 biomarkers (IL8, MMP9, MMP10, SERPINA1, VEGFA, ANG, CA9, APOE, SDC1, and SERPINE1) were measured using commercial ELISA assays in an external laboratory. The diagnostic performance of the biomarker panel was assessed using receiver operator curves (ROC) and descriptive statistical values. Results: Utilizing the combination of all 10 biomarkers, the area under the ROC for the diagnostic panel was noted to be 0.847 (95% confidence interval, 0.796–0.899), outperforming any single biomarker. The multiplex assay at optimal cutoff value achieved an overall sensitivity of 0.79, specificity of 0.79, positive prediction value of 0.73, and negative prediction value of 0.84 for bladder cancer classification. Sensitivity values of the diagnostic panel for high-grade bladder cancer, low-grade bladder cancer, muscle invasive bladder cancer, and non-muscle invasive bladder cancer were 0.81, 0.90, 0.95, and 0.77, respectively. Conclusions: Urinary levels of the biomarker panel enabled discrimination of patients with bladder cancer and controls, and the levels of biomarker subsets were associated with advancing tumor grade and stage. Impact: If proven to be reliable, urinary diagnostic biomarker assays can detect bladder cancer in a timely manner such that the patient can expect improvements in overall survival and quality of life. Cancer Epidemiol Biomarkers Prev; 23(9); 1804–12. ©2014 AACR.
Pheochromocytoma and Paraganglioma: An Endocrine Society Clinical Practice Guideline
Lenders, Jacques W.M. , Duh, Quan‐Yang , Eisenhofer, Graeme, Gimenez‐Roqueplo, Anne‐Paule , Grebe, Stefan K., Murad, M. Hassan , Eisenhofer, Graeme, Naruse, Mitsuhide , Pacák, Karel , Young, William F. , Murad, M Hassan , Gimenez-Roqueplo, Anne-Paule

The Journal of Clinical Endocrinology & Metabolism | June 3, 2014 | Volume: 99 | Issue: 6 | Pages: 1915-1942

10.1210/jc.2014-1498 | PMID 24893135 Get It

Patient survival after surgical treatment of rectal cancer: Impact of surgeon and hospital characteristics
Etzioni, David A. , Young‐Fadok, Tonia M., Wasif, Nabil , Madoff, Robert D. , Naessens, James M. , Habermann, Elizabeth B. , Cima, Robert R. , Habermann, Elizabeth

Cancer | May 6, 2014 | Volume: 120 | Issue: 16 | Pages: 2472-2481

10.1002/cncr.28746 | PMID 24802276 Get It

BACKGROUNDSurgeon and hospital factors are associated with the survival of patients treated for rectal cancer. The relative contribution of each of these factors toward determining outcomes is poorly understood.METHODSWe used data from the Surveillance, Epidemiology, and End Results–Medicare database to analyze the outcomes of patients aged 65 years and older undergoing operative treatment for nonmetastatic rectal cancer, diagnosed in the United States between 1998 and 2007. These data were linked to a registry to identify whether the treating surgeon was a board‐certified colorectal surgeon versus a noncolorectal surgeon. Hospital volume and hospital certification as a National Cancer Institute–designated Comprehensive Cancer Centers were also analyzed. The primary outcome of interest was long‐term survival.RESULTSOur data source yielded 6432 patients. Initial analysis demonstrated improved long‐term survival in patients treated by higher‐volume colorectal surgeons, higher‐volume hospitals, teaching hospitals, and National Cancer Institute (NCI)–designated Comprehensive Cancer Centers. Based on an iterative approach to modeling the interactions between these various factors, we found a robust effect of surgeon subspecialty status, hospital volume, and NCI designation. Surgeon volume was not distinctly associated with long‐term survival.CONCLUSIONSPatients treated for rectal cancer by board‐certified colorectal surgeons in centers that are higher volume and/or NCI‐designated Comprehensive Cancer Centers experience better overall survival. These differences persist after adjustment for a broad range of patient and contextual risk factors, including surgeon volume. Patients and payers can use these results to identify surgeons and hospitals where outcomes are most favorable. Cancer 2014;120:2472–2481. © 2014 American Cancer Society.
Usefulness of dynamic MRI enhancement measures for the diagnosis of ACTH‐producing pituitary adenomas
Guo, Qinghua , Erickson, Dana , Young, William F. , Erickson, Bradley J.

Clinical Endocrinology | May 6, 2014 | Volume: 82 | Issue: 2 | Pages: 267-273

10.1111/cen.12475 | PMID 24801354 Get It

SummaryPurposeThe distinction between corticotropin (ACTH)‐producing pituitary adenomas and occult ectopic ACTH neoplasms is a challenge and frequently complicated by the detection of nonfunctioning pituitary adenomas on dynamic magnetic resonance imaging (DMRI). Herein, we explored quantitative differences in DMRI measures from ACTH‐producing pituitary adenomas.Materials and methodsFifty‐five patients with pathology confirmed ACTH‐producing and 44 with nonfunctioning pituitary adenomas were analysed in this retrospective pilot study. The intensities of adenomas and of adjacent pituitary tissue were measured by drawing a region of interest. Time–intensity curves were then constructed, and quantitative analysis included: enhancement time, enhancement peak and prepeak slope (PPS). Multivariable logistic analysis and receiver operating characteristic curves (ROC) were used to evaluate the parameters.ResultsQuantitative analysis showed that tumour PPS in ACTH‐producing adenomas was markedly lower than that in nonfunctioning adenomas (P = 0·0042) and that the PPS of the adjacent pituitary gland was not different (P = 0·2441). The PPS was >3·0 in 59·1% of nonfunctioning adenomas and ≤3·0 in 69·1% of ACTH‐producing adenomas (P = 0·0049). Logistic analysis revealed lower tumour PPS levels (P = 0·0123, OR 1·24, 95% CI: 1·05–1·52) were associated with ACTH‐producing adenomas. The optimal PPS cut‐off determined by ROC analysis was 2·89, with a sensitivity of 69% and specificity of 70%. No significant difference was found between the two groups in enhancement time or enhancement peak.ConclusionEnhancement parameters in DMRI can help distinguishing ACTH producing from nonfunctioning pituitary adenomas, which could be useful in the differential diagnosis between ACTH‐producing pituitary adenomas and ectopic ACTH syndrome complicated with nonfunctioning pituitary adenoma.
Accuracy of Adrenal Imaging and Adrenal Venous Sampling in Predicting Surgical Cure of Primary Aldosteronism
Lim, Vivien , Guo, Qinghua , Grant, Clive S., Thompson, Geoffrey B. , Richards, Melanie L. , Farley, David R. , Young, William F.

The Journal of Clinical Endocrinology & Metabolism | May 5, 2014 | Volume: 99 | Issue: 8 | Pages: 2712-2719

10.1210/jc.2013-4146 | PMID 24796926 Get It

Boy With Yellow-Orange, Rough Nodule on Right Thigh
Flores, Sara Elia Hernández, Johnson, Jonathan N. , Young, Phillip M. , Tollefson, Megha M. , Johnson, Jonathan, Young, Phillip, Tollefson, Megha

JAMA Pediatrics | May 3, 2014 | Volume: 168 | Issue: 5 | Pages: 493

10.1001/jamapediatrics.2013.3979 | PMID 24791740 Get It

A3 Adenosine Receptor Signaling Contributes to Airway Inflammation and Mucus Production in Adenosine Deaminase-Deficient Mice
Young, Hays W. J., Molina, Jose G., Dimina, Dawn, Zhong, Hongyan, Jacobson, Marlene A. , Chan, Lee-Nien L., Chan, Teh‐Sheng, Lee, James J. , Blackburn, Michael R.

The Journal of Immunology | April 20, 2014 | Volume: 173 | Issue: 2 | Pages: 1380-1389

10.4049/jimmunol.173.2.1380 | PMID 15240734 Get It

Abstract Adenosine signaling has been implicated in chronic lung diseases such as asthma and chronic obstructive pulmonary disease; however, the specific roles of the various adenosine receptors in processes central to these disorders are not well understood. In this study, we have investigated the role(s) of the A3 adenosine receptor in adenosine-dependent pulmonary inflammation observed in adenosine deaminase (ADA)-deficient mice. The A3 receptor (A3R) was found to be expressed in eosinophils and mucus-producing cells in the airways of ADA-deficient mice. Treatment of ADA-deficient mice with MRS 1523, a selective A3R antagonist, prevented airway eosinophilia and mucus production. Similar findings were seen in the lungs of ADA/A3 double knockout mice. Although eosinophils were decreased in the airways of ADA-deficient mice following antagonism or removal of the A3R, elevations in circulating and lung interstitial eosinophils persisted, suggesting signaling through the A3R is needed for the migration of eosinophils into the airways. These findings identify an important role for the A3R in regulating lung eosinophilia and mucus production in an environment of elevated adenosine.
Anesthetic-related Neurotoxicity in the Young and Outcome Measures
Flick, Randall P., Nemergut, Michael E. , Christensen, Kaare , Hansen, Tom G. , Christensen, Kaare

Anesthesiology | April 4, 2014 | Volume: 120 | Issue: 6 | Pages: 1303-1305

10.1097/aln.0000000000000249 | PMID 24705443 Get It

Noninvasive Evaluation of Coronary Collateral Arterial Flow by Coronary Computed Tomographic Angiography
Kim, Eun Kyoung , Kim, Sung Mok , Song, Young Bin , Gwon, Hyeon‐Cheol , Lee, Sang Hoon , Oh, Jae K. , Hahn, Joo‐Yong , Choe, Yeon Hyeon , Choi, Jin‐Ho , Song, Young Bin , Choi, Seung‐Hyuk

Circulation: Cardiovascular Imaging | April 4, 2014 | Volume: 7 | Issue: 3 | Pages: 482-490

10.1161/circimaging.113.001637 | PMID 24700691 Get It

Background— Coronary collateral flow is an alternative source of myocardial perfusion in patients with totally occluded coronary arteries. Clinical evaluation of collateral flow has been limited by the need of invasive measurements. We investigated whether noninvasive coronary computed tomographic angiography can evaluate the angiographic extent of coronary collateral flow. Methods and Results— We enrolled 325 coronary computed tomographic angiography cases with angiographically confirmed chronic total occlusion (median age, 63 years; men 83%). Transluminal attenuation gradient (TAG), which reflects the kinetics of contrast media in coronary artery, of an entire artery as well as of a distal vessel was assessed to evaluate the flow in entire vessel and distal vessel. TAGs were validated against visually assessed angiographic collateral connection and Rentrop grading. TAG of an entire artery increased consistently according to the angiographic extent of collateral flow ( P <0.001). Well-developed collaterals, defined by highest collateral connection and Rentrop grades (n=103), could be predicted by TAG of an entire artery (cutoff, ≥−7.6 Hounsfield units/10 mm; c -statistics, 0.72; sensitivity, 65%; specificity, 73%; positive predictive value, 52%; negative predictive value, 82%). TAG of a distal vessel could discriminate the antegrade (n=143) and retrograde (n=182) flows in distal artery (cutoff, 0.0 Hounsfield unit/10 mm; c -statistics, 0.88; sensitivity, 78%; specificity, 85%; positive predictive value, 87%; negative predictive value, 75%). Conclusions— TAG, an intracoronary attenuation-based analysis of coronary computed tomographic angiography, moderately reflected the functional extent and direction of collateral flow.